Open-label, multicenter, phase 1 study of alisertib...

  • Main
  • 2016 / 05
  • Open-label, multicenter, phase 1 study of alisertib...
Cancer 2016 / 05

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

Graff, Julie N., Higano, Celestia S., Hahn, Noah M., Taylor, Matthew H., Zhang, Bin, Zhou, Xiaofei, Venkatakrishnan, Karthik, Leonard, E. Jane, Sarantopoulos, John
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Cancer
DOI:
10.1002/cncr.30073
Date:
May, 2016
File:
PDF, 252 KB
english, 2016
Conversion to is in progress
Conversion to is failed